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Abstract
Background
Data are limited on genome-wide association studies (GWAS) for incident coronary heart
disease (CHD). Moreover, it is not known whether genetic variants identified to date also
associate with risk of CHD in a prospective setting.
Methods
We performed a two-stage GWAS analysis of incident myocardial infarction (MI) and CHD in
a total of 64,297 individuals (including 3898MI cases, 5465 CHD cases). SNPs that passed
an arbitrary threshold of 5×10−6 in Stage I were taken to Stage II for further discovery. Further-
more, in an analysis of prognosis, we studied whether known SNPs from former GWASwere
associated with total mortality in individuals who experienced MI during follow-up.
Results
In Stage I 15 loci passed the threshold of 5×10−6; 8 loci for MI and 8 loci for CHD, for which
one locus overlapped and none were reported in previous GWASmeta-analyses. We took
GWAS for Incident MI and CHD
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60 SNPs representing these 15 loci to Stage II of discovery. Four SNPs nearQKI showed
nominally significant association with MI (p-value<8.8×10−3) and three exceeded the
genome-wide significance threshold when Stage I and Stage II results were combined (top
SNP rs6941513: p = 6.2×10−9). Despite excellent power, the 9p21 locus SNP (rs1333049)
was only modestly associated with MI (HR = 1.09, p-value = 0.02) and marginally with CHD
(HR = 1.06, p-value = 0.08). Among an inception cohort of those who experienced MI during
follow-up, the risk allele of rs1333049 was associated with a decreased risk of subsequent
mortality (HR = 0.90, p-value = 3.2×10−3).
Conclusions
QKI represents a novel locus that may serve as a predictor of incident CHD in prospective
studies. The association of the 9p21 locus both with increased risk of first myocardial infarc-
tion and longer survival after MI highlights the importance of study design in investigating
genetic determinants of complex disorders.
Introduction
There is strong and consistent evidence that coronary heart disease (CHD) is highly heritable
and is influenced by a wide range of genetic factors [1, 2]. Recently genome-wide association
studies (GWAS) identified common genetic variants involved in cardiovascular disease and its
risk factors [3]. The loci reported by the latest and largest GWAS altogether explain around
10% of CHD heritability [4].
To date, GWAS for CHD have been conducted mostly in cross-sectional case-control setting,
and this design, which uses prevalent cases, typically oversamples those with long post-event sur-
vival times. Although such a design often makes it possible to collect information from a large
number of patients, this approach may incorrectly identify factors that are associated with a high
or low case-fatality rate. For instance, a factor associated with a low case-fatality will be enriched
among surviving cases and may appear to increase the risk of disease when prevalent cases are
compared with controls. This bias is known as incidence-prevalence (Neyman) bias [5, 6]. One
major advantage of studying incident cases rather than prevalent cases is that incident cases
properly represent the fatal cases and persons with only brief post-event survival. To date the
strong and reliable evidence for identifying and assessing factors such as LDL-cholesterol and
systolic blood pressure that predict future clinical disease are provided by well-designed popula-
tion-based, prospective cohort studies that collect large number of incident cases [7].
Here we aimed to study genetic variants that affect the incidence of myocardial infarction
(MI) and CHD in prospective, population-based cohorts and whether the genetic variants
identified to date are also associated with risk of CHD in a prospective setting. Moreover, we
investigated whether the known genetic variants are associated with total-mortality after MI.
To this end we used the data from the Cohorts for Heart and Aging Research in Genome Epi-
demiology (CHARGE) Consortium [8] and collaborating prospective studies.
Methods
Study Population
We performed our study in two stages. Stage I studies comprised participants from five pro-
spective cohort studies that form the CHARGE consortium [8]: the Age, Gene Environment
GWAS for Incident MI and CHD
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Susceptibility Reykjavik Study (AGES) [9]; the Atherosclerosis Risk in Communities (ARIC)
Study [10]; the Cardiovascular Health Study (CHS) [11]; the Framingham Heart Study (FHS)
[12]; and the Rotterdam Study (RS) [13, 14]. Stage II comprised individuals from: The Health,
Aging, and Body Composition (Health ABC) Study; The Health Professionals Follow-Up
Study (HPFS); The Nurses’ Health Study (NHS); PROSPER/PHASE Study; the Study of Health
in Pomerania (SHIP); The Women’s Genome Health Study (WGHS); the MOnica Risk, Genet-
ics, Archiving and Monograph (MORGAM) Study comprising the Alpha-Tocopherol, Beta-
Carotene (ATBC) Study; The FINRISK Study; The PRIME Study (including the PRIME
cohorts of Belfast, Lille, Strasbourg and Toulouse); The Northern Sweden Study. Participants
in Stages I and II were of European ancestry. Participants with a history of MI or CHD at base-
line were excluded. All studies had protocols approved by local institutional review boards.
Participants provided written informed consent and gave permission to use their DNA for
research purposes. The Supplementary Document provides details about the design and char-
acteristics for these studies.
Case Definitions for MI and CHD
The definitions of incident MI were consistent among the participating studies, including both
fatal and non-fatal MI. CHD included fatal or non-fatal MI, and in most studies fatal CHD or
sudden death. The definition of MI and CHD for each cohort study is summarized in S1 Table
and S2 Table.
Statistical Analysis
The date of entry to the analysis was the date of cohort entry (AGES, ARIC, CHS, RS) or DNA
collection (FHS). Within each study, Cox proportional hazards regression models were used to
test the association between each SNP and time to incident MI or CHD, while adjusting for sex
and baseline age. FHS adjusted for familial correlation by clustering on pedigree. Analyses in
CHS and ARIC were adjusted for study site and in FHS, for generation and additionally for
ancestry using principal components [15]. The censor date was the time of MI or CHD diagno-
sis, the time of death, last date of contact, or at the end of follow-up, whichever came first. For
each SNP, additive genetic models were used to estimate the regression coefficient for the haz-
ard ratio (HR) for allele dosage and its respective standard error. For each analysis, a genomic
control coefficient (λ) was calculated, which estimated the extent of underlying population
structure. Further information on the analysis methods can be found in S3 Table and S4 Table.
Information regarding the genotyping and imputation as well as genotype quality control
are found in S5 Table and S6 Table. SNPs with a minor allele frequency of less than 1%, impu-
tation quality less than 0.3 or very large regression coefficients (absolute value larger than 5)
were excluded from meta-analysis. Results from individual studies were meta-analyzed for a
total of 2,543,842 autosomal SNPs based on Phase 2 HapMap. A fixed effects inverse variance
weighted meta-analysis approach was implemented in METAL [16] to combine the regression
coefficients and their standard errors, producing a summary regression coefficient and stan-
dard error from which a p-value was computed. An arbitrary significance threshold for follow-
up in Stage II was set at 5.0×10−6. When more than one SNP clustered at a locus, we carried
forward four SNPs with smallest p-values in the associated locus for further investigation in
Stage II.
In Stage II, three studies provided data both for incident MI and CHD (HABC, MORGAM,
andWGHS), two studies provided data only for MI (PROSPER, SHIP), and two others pro-
vided data only for CHD (HPFS, NHS). Each Stage II study used the same analytic method as
used in Stage I to examine the association of the 60 SNPs with MI or CHD. As in the Stage I
GWAS for Incident MI and CHD
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meta-analysis, we used inverse-variance weighted fixed effects meta-analysis to evaluate the
Stage II results. We applied a Bonferroni correction for 60 SNPs and set 8.3×10−4 as the signifi-
cance threshold. Finally, results from all studies in Stage I and II were combined using inverse-
variance weighted fixed effects meta-analysis.
We further studied each of the 46 SNPs reported by the CARDIoGRAMplusC4D Consor-
tium [4], for association with incident events in our meta-analysis of longitudinal cohort stud-
ies. Moreover, the SNPs were combined into a weighted genetic risk score using beta estimates
from the CARDIoGRAMplusC4D Consortium report [4]. The association of each SNP, as well
as the score from the combination of all 46 SNPs, was examined with incident MI and CHD
using the results of Stage I meta-analysis.
We applied a Cox proportional hazards model adjusted for age and sex to examine the asso-
ciation of the known SNPs with mortality after MI. Five studies including AGES, ARIC, CHS,
FHS and the Rotterdam Study provided data for this analysis and in total 2953 individuals
were followed after incidence of MI of which 1828 died. The median follow up time ranged
from 2.3 years in AGES to 4.7 years in FHS. The baseline characteristics of the study popula-
tions for this analysis are presented in S7 Table. Since this analysis was meant to explore poten-
tial reasons for weak association or lack of association with incident MI and CHD, we limited
the analysis to three SNPs with more than 80% power in Stage I to study its estimated associa-
tions with incident MI and CHD.
Results
Fig 1 describes Stage I and Stage II of the study. The Stage I panel included five prospective
cohort studies comprising a total of 24,024 participants who were free of MI and CHD at base-
line. The average age ± standard deviation ranged from 54.1±5.6 in ARIC to 74.6±5.5 in AGES.
More than half of the participants (54.5%) were women. The basic characteristics of the partici-
pating studies are shown in Table 1. A total of 1570 incident MI events (6.5%) and 2406 inci-
dent CHD events (10.0%) occurred over an average of 8.2 years and 8.1 years of follow-up for
MI and CHD, respectively. The average age at the time of MI ranged from 65.2 years in ARIC
to 80.8 years in CHS.
The λ coefficient within each cohort was small (1.03), suggesting negligible genomic infla-
tion. We combined the results of associations for all SNPs across the five cohorts. S1A Fig and
S1B Fig presents the Q-Q plots of combined p-values against the expected p-value distribution
for MI and CHD, respectively. The evidence for population admixture was small, both for MI
(λ = 1.017) and CHD (λ = 1.022). S2A Fig and S2B Fig illustrates the p-values of the meta-anal-
ysis for each of the SNPs across the 22 autosomal chromosomes for MI and CHD, respectively.
In Stage I, 27 SNPs in 8 loci reached our arbitrary threshold of 5×10−6 for MI and 29 SNPs
in 8 loci reached this threshold for CHD (Table 2). The most significant association with MI
was seen for rs6941513 located on chromosome 6 upstream of QKI (Hazard Ratio = 1.22 [95%
Confidence Interval: 1.13, 1.31], p-value = 2.0×10−7). For CHD, rs986080, a SNP located on
chromosome 1 between two genes (SNX7 and PAP2D) showed the strongest association
(HR = 1.19 [95%CI: 1.12, 1.27], p-value = 6.6×10−8).
In Stage II, we sought additional evidence for associations in eight loci for MI (QKI, ODZ3,
DGKB, FOXL1, CALCOCO2, BARD1, COL8A1, ATXN1) and eight loci for CHD (PAP2D,
GPC5, CTNNA3, BARHL2, IGFBP3, LRFN2, ATXN1, SNCA) using four SNPs per locus, for a
total of 60 SNPs in 15 loci (ATXN1 was associated with both MI and CHD). Baseline character-
istics of the participants of Stages II are shown in S8 and S9 Tables. The results for all 60 SNPs
are presented in S10 Table and S11 Table, for MI and CHD, respectively. None of the SNPs
passed the Bonferroni adjusted threshold of 8.3×10−4. The results for the best association in
GWAS for Incident MI and CHD
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Fig 1. Study design for identification and validation of SNPs associated with MI and CHD.
doi:10.1371/journal.pone.0144997.g001
GWAS for Incident MI and CHD
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Table 1. Baseline characteristics of participants included in incident MI/CHD analysis stratified by cohort.
Characteristic AGES ARIC CHS FHS RS
Participants, n 3219 7406 3291 4134 5974
Age, years 76.4 (5.5) 54.1 (5.57) 72.3 (5.4) 64.5 (12.8) 69.4 (9.1)
Women, % 58.0 54.7 39.1 56.7 59.4
Hypertension1, % 80.6 25.7 52.8 45.3 33.4
Diabetes2, % 11.5 7.7 11.8 10.2 10.6
Current smoker3, % 12.7 24.8 11.3 14.0 22.4
Total cholesterol, mg/dL 217 (45) 214 (41) 213 (39) 203 (40) 255 (47)
HDL cholesterol, mg/dL 61 (17) 51 (17) 55 (16) 52 (17) 52 (14)
Triglyceride, mg/dL 107 (59) 135 (91) 140 (76) 144 (127) NA
Body mass index, kg/m2 27.1 (4.4) 27.0 (4.9) 26.3 (4.5) 27.7 (5.2) 26.3 (3.7)
Incident MI, N cases 86 486 537 165 296
Mean MI follow-up time 2.7 9.2 12.0 5.5 10.1
Incident CHD, N cases 209 575 660 201 761
Mean CHD follow-up time 2.6 9.1 12.0 5.5 9.9
Incident MI Age, years 79.1 (5.5) 65.17 (6.9) 80.8 (6.2) 75.2 (12.2) 80.6 (10.1)
Numbers in table are Mean (SD) or percentage. AGES = Age, Gene/Environment Study; ARIC = Atherosclerosis Risk in Communities Study;
CHS = Cardiovascular Health Study; FHS = Framingham Heart Study; HDL = high density lipoprotein; RS = The Rotterdam Study
1 Hypertension was deﬁned as blood pressure 140/90 mmHg or on anti-hypertensive medication
2 Diabetes was deﬁned as fasting blood glucose >125 mg/dL, a random blood glucose of >200 mg/dL, or use of insulin or oral hypoglycemic agents
(Rotterdam: diabetes deﬁnition: Using anti-diabetic medication or random glucose or oral glucose test more than 200 mg/dl)
3 Current cigarette smoking was deﬁned as self-reported cigarette smoking of at least 1 cigarette per day for a year at any attended exam
doi:10.1371/journal.pone.0144997.t001
Table 2. Description and association of SNPs of the top loci associated with incident MI and CHD in Stage I.
Phenotype SNP Band Alleles* HR (95%CI) P-value Gene Location
MI rs6941513 6q26 G/A 1.22 (1.13–1.31) 2.0×10−7 QKI Closest gene
rs13139636 4q35.1 T/A 1.44 (1.25–1.66) 6.4×10−7 ODZ3 Intron
rs217597 7p21.2 T/C 1.26 (1.15–1.38) 1.3×10−6 DGKB Intron
rs9923194 16q24.1 C/T 1.88 (1.44–2.44) 1.9×10−6 FOXL1 Closest gene
rs6504582 17q21.32 A/G 1.20 (1.11–1.30) 2.1×10−6 CALCOCO2 Closest gene
rs7591615 2q35 T/C 1.21 (1.12–1.32) 3.3×10−6 BARD1 Intron
rs17777478 3q12.1 T/A 1.73 (1.37–2.20) 4.4×10−6 COL8A1 Intron
rs2299063 6p22.3 A/C 1.24 (1.13–1.37) 4.8×10−6 ATXN1 Intron
CHD rs986080 1p21.3 C/T 1.19 (1.12–1.27) 6.6×10−8 PAP2D Intron
rs16945166 13q31.3 G/A 1.34 (1.20–1.51) 4.7×10−7 GPC5 Closest gene
rs10740220 10q21.3 G/T 1.20 (1.11–1.29) 1.0×10−6 CTNNA3 Intron
rs10922855 1p22.2 T/G 1.22 (1.12–1.33) 1.9×10−6 BARHL2 Closest gene
rs7794677 7p12.3 T/C 1.20 (1.11–1.29) 2.3×10−6 IGFBP3 Closest gene
rs2916260 6p21.2 T/C 1.21 (1.12–1.31) 2.8×10−6 LRFN2 Intron
rs3812189 6p22.3 C/T 1.21 (1.12–1.31) 3.1×10−6 ATXN1 Intron
rs356228 4q22.1 G/C 1.16 (1.09–1.23) 3.2×10−6 SNCA Closest gene
*Coded/non-coded allele
HR = Hazard Ratio; CI = Conﬁdence Interval
doi:10.1371/journal.pone.0144997.t002
GWAS for Incident MI and CHD
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each locus are shown in Table 3. Four SNPs located upstream of QKI showed nominal evidence
in Stage II for association with MI. The analysis of the combined Stage I and Stage II yielded
genome-wide significant associations for three SNPs close to QKI, (rs6941513: HR = 1.21 [95%
CI: 1.13, 1.28], p-value = 6.2×10−9). Fig 2 presents the linkage disequilibrium (LD) and p-values
of regional markers for this locus. We tested for evidence of replication of this association in
8201 African American individuals including 546 incident cases from the PAGE Study [17],
however, rs6941513 was not significantly associated with risk of MI in this population
(p = 0.49).
We sought evidence for the association of 46 SNPs recently reported in the largest GWAS to
date for coronary artery disease [4] with the incidence of MI and CHD (Table 4). Despite excel-
lent power, we found only modest evidence for replication of the association with 9p21 locus
(CDKN2A/B), the most established finding from previous cross-sectional case-control GWAS.
The most replicated SNP at 9p21 locus, rs1333049, was nominally associated with MI (HR:
1.09 [95%CI: 1.01, 1.18], p-value = 0.02) and marginally with CHD (HR = 1.06 [95%CI: 0.99,
1.13], p-value = 0.08). The most significant association with MI was found for rs15563, a SNP
in UBE2Z (HR: 1.12 [95%CI: 1.04, 1.20], p-value = 1.9×10−3) and the most significant associa-
tion with CHD was found for rs10947789, a SNP within the KCNK5 locus (HR: 1.13 [95%CI:
1.05, 1.22], p-value = 5.6×10−4). We found nominally significant associations (p<0.05) with
SNPs annotated to CDKN2A/B for MI, LIPA for CHD and COL4A2, TCF21, PDGFD, KCNK5,
VAMP8,MRAS, UBE2Z and TCF21 for both MI and CHD (Table 4). A weighted genetic risk
score composed of these 46 SNPs was associated with MI (p-value = 1.3×10−3) and CHD (p-
value = 1.2×10−3) in the Stage I meta-analysis.
Among individuals who experienced MI during follow-up, the risk allele of rs1333049 was
associated with a significantly decreased risk of mortality (HR: 0.90 [95% CI: 0.84, 0.97], p-
value = 5.5×10−3) (Table 5). In both SNPs at 9p21 locus the “risk allele” from cross-sectional
Table 3. Description and association of top SNPs with incident MI and CHD in Stage II and their combined results with Stage I.
Phenotype SNPID Alleles* Stage II Combined Closest Gene
HR (95%CI) P-value HR (95%CI) P-value
MI rs6941513 G/A 1.16 (1.04–1.31) 8.8×10−3 1.2 (1.13–1.28) 6.2×10−9 QKI
rs7692395 T/G 1.03 (0.75–1.40) 0.86 0.69 (0.59–0.79) 2.5×10−7 ODZ3
rs4721377 T/G 0.98 (0.87–1.10) 0.73 1.26 (1.14–1.38) 1.9×10−6 DGKB
rs9923194 C/T 1.04 (0.69–1.58) 0.84 1.58 (1.27–1.97) 4.3×10−5 FOXL1
rs6504582 A/G 1.03 (0.91–1.15) 0.65 1.15 (1.08–1.22) 1.8×10−5 CALCOCO2
rs7591615 T/C 0.89 (0.78–1.02) 0.09 1.11 (1.03–1.19) 3.8×10−3 BARD1
rs17777478 T/A 1.15 (0.80–1.64) 0.45 1.54 (1.26–1.88) 1.6×10−5 COL8A1
rs2299063 A/C 0.93 (0.81–1.07) 0.29 1.13 (1.05–1.23) 1.6×10−3 ATXN1
CHD rs986080 C/T 0.97 (0.91–1.04) 0.39 0.97 (0.91–1.04) 1.1×10−3 PAP2D
rs16945166 G/A 1.02 (0.92–1.14) 0.69 1.02 (0.92–1.14) 2.2×10−4 GPC5
rs10509258 C/T 1.02 (0.96–1.09) 0.50 1.02 (0.96–1.09) 3.0×10−4 CTNNA3
rs12031583 G/A 0.89 (0.79–1.00) 0.05 0.89 (0.79–1.00) 7.8×10−3 BARHL2
rs1551837 A/G 1.03 (0.94–1.12) 0.58 1.03 (0.94–1.12) 2.3×10−4 IGFBP3
rs6925172 C/T 1.12 (1.01–1.25) 0.04 1.12 (1.01–1.25) 3.3×10−6 LRFN2
rs9297015 T/A 0.93 (0.86–1.01) 0.07 0.93 (0.86–1.01) 0.12 ATXN1
rs356228 G/C 1.02 (0.96–1.09) 0.50 1.02 (0.96–1.09) 1.7×10−4 SNCA
*Coded/non-coded allele
Chr. = Chromosome; HR = Hazard Ratio; CI = Conﬁdence Interval
doi:10.1371/journal.pone.0144997.t003
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case-control GWAS was associated with longer survival after MI and would have been enriched
in surviving prevalent cases. Fig 3 illustrates the inverse association of 78 top SNPs at the 9p21
locus as reported by CARDIoGRAMplusC4D Consortium [4] with survival after MI. We also
examined the association of rs6941513 with mortality after MI, however, the association was
not significant.
Discussion
We performed a GWAS on incident MI and CHD and examined whether the gene variants
identified to date are also associated with risk of CHD in a prospective setting. In a two-stage
design, involving 37,561 participants with 2,328 cases of incident MI, we identified a novel
genome-wide significant locus, QKI, associated with incident MI. This finding requires further
replication. The results also highlighted the difference between the genes identified in prospec-
tive versus cross-sectional case-control studies. The 9p21 locus was associated with both an
increased risk of incident MI and, during follow-up post-MI, a decreased risk of total mortality,
indicating that genetic variants may operate differently in an alternative setting.
Fig 2. Regional plots for the association of SNPs with MI in the region ofQKI.
doi:10.1371/journal.pone.0144997.g002
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Table 4. Association of the known SNPs for coronary artery disease with incident MI and CHD in Stage I.
SNP Chr. Freq. Alleles* Reported
GWAS
GWAS on Incident MI GWAS on Incident CHD Gene
OR P-value Power HR (95% CI) P-value Power HR (95% CI) P-value
rs3217992 9 0.38 A/G 1.16 7.8×10−57 0.98 1.07 (0.99–1.15) 0.10 0.99 1.04 (0.98–1.11) 0.21 CDKN2A/B
rs1333049 9 0.47 C/G 1.23 1.4×10−52 0.99 1.09 (1.01–1.18) 0.02 0.99 1.06 (0.99–1.13) 0.08 CDKN2A/B
rs602633 1 0.77 C/A 1.12 1.5×10−25 0.73 1.08 (0.99–1.17) 0.10 0.89 1.05 (0.97–1.12) 0.21 PSRC1
rs9369640 6 0.65 A/C 1.09 7.5×10−22 0.62 1.05 (0.98–1.13) 0.17 0.78 1.03 (0.97–1.10) 0.27 PHACTR1
rs11556924 7 0.65 C/T 1.09 6.7×10−17 0.62 1.05 (0.97–1.14) 0.26 0.78 1.06 (0.99–1.14) 0.07 ZC3HC1
rs9982601 21 0.13 T/C 1.13 7.7×10−17 0.63 0.98 (0.88–1.09) 0.68 0.79 1.01 (0.93–1.10) 0.81 MRPS6
rs6725887 2 0.11 C/T 1.12 1.2×10−15 0.51 1.06 (0.95–1.18) 0.29 0.67 0.99 (0.90–1.08) 0.78 WDR12
rs1122608 19 0.76 G/T 1.10 6.3×10−14 0.62 1.07 (0.98–1.16) 0.13 0.77 1.04 (0.97–1.12) 0.23 SMARCA4
rs12190287 6 0.59 C/G 1.07 4.9×10−13 0.45 1.13 (1.04–1.23) 4.4×10−3 0.60 1.09 (1.01–1.16) 0.02 TCF21
rs7173743 15 0.58 T/C 1.07 6.7×10−13 0.45 1.05 (0.97–1.13) 0.23 0.60 1.04 (0.98–1.10) 0.23 MORF4L1
rs17114036 1 0.91 A/G 1.11 5.8×10−12 0.39 1.12 (0.97–1.28) 0.11 0.52 1.06 (0.95–1.19) 0.27 PPAP2B
rs9515203 13 0.74 T/C 1.08 5.9×10−12 0.46 1.06 (0.95–1.17) 0.31 0.61 1.07 (0.99–1.17) 0.09 COL4A2
rs2505083 10 0.42 C/T 1.06 1.4×10−11 0.35 1.05 (0.97–1.13) 0.19 0.47 1.03 (0.97–1.10) 0.36 KIAA1462
rs4773144 13 0.42 G/A 1.07 1.4×10−11 0.45 1.09 (1.01–1.18) 0.03 0.60 1.09 (1.02–1.16) 0.01 COL4A2
rs7692387 4 0.81 G/A 1.06 2.7×10−11 0.39 1.00 (0.91–1.09) 0.95 0.52 1.01 (0.93–1.09) 0.83 GUCY1A3
rs974819 11 0.29 A/G 1.07 3.6×10−11 0.39 0.91 (0.83–0.98) 0.02 0.53 0.93 (0.87–1.00) 0.04 PDGFD
rs3184504 12 0.40 T/C 1.07 5.4×10−11 0.44 1.03 (0.95–1.11) 0.47 0.60 1.04 (0.98–1.11) 0.22 SH2B3
rs2075650 19 0.14 G/A 1.11 5.9×10−11 0.53 1.03 (0.91–1.16) 0.67 0.68 1.01 (0.91–1.13) 0.79 TOMM40
rs2048327 6 0.35 G/A 1.06 6.9×10−11 0.33 1.00 (0.93–1.08) 0.98 0.45 1.01 (0.95–1.08) 0.65 SLC22A3
rs9319428 13 0.32 A/G 1.05 7.3×10−11 0.32 0.99 (0.91–1.09) 0.91 0.43 1.03 (0.96–1.11) 0.44 FLT1
rs17514846 15 0.44 A/C 1.05 9.3×10−11 0.45 1.00 (0.93–1.08) 0.94 0.60 1.02 (0.96–1.09) 0.52 FURIN
rs1561198 2 0.45 A/G 1.05 1.2×10−10 0.35 1.09 (1.01–1.17) 0.02 0.48 1.09 (1.02–1.15) 6.9×10−3 VAMP8
rs515135 2 0.83 G/A 1.08 2.6×10−10 0.29 1.09 (0.98–1.20) 0.10 0.40 1.03 (0.95–1.12) 0.52 APOB
rs4845625 1 0.47 T/C 1.04 3.6×10−10 0.36 1.01 (0.94–1.08) 0.86 0.48 1.03 (0.97–1.10) 0.28 IL6R
rs2895811 14 0.43 C/T 1.06 4.1×10−10 0.35 1.03 (0.95–1.11) 0.44 0.48 1.03 (0.96–1.10) 0.39 KIAA1822
rs4252120 6 0.73 T/C 1.06 4.9×10−10 0.38 0.99 (0.92–1.07) 0.82 0.51 0.99 (0.93–1.06) 0.74 PLG
rs273909 5 0.14 C/T 1.09 9.6×10−10 0.26 1.04 (0.91–1.17) 0.59 0.35 1.01 (0.91–1.12) 0.84 SLC22A4
rs12936587 17 0.59 G/A 1.06 1.2×10−9 0.35 1.00 (0.92–1.08) 0.94 0.47 0.97 (0.91–1.04) 0.40 RAI1
rs2047009 10 0.48 C/A 1.05 1.6×10−9 0.27 1.02 (0.94–1.09) 0.68 0.36 1.03 (0.97–1.1) 0.30 CXCL12
rs501120 10 0.83 A/G 1.07 1.8×10−9 0.29 1.08 (0.96–1.21) 0.18 0.39 1.00 (0.91–1.09) 0.96 CXCL12
rs9818870 3 0.14 T/C 1.07 2.6×10−9 0.26 1.10 (1.00–1.21) 0.05 0.35 1.09 (1.01–1.18) 0.02 MRAS
rs264 8 0.86 G/A 1.05 2.9×10−9 0.53 0.99 (0.89–1.10) 0.83 0.68 1.05 (0.96–1.14) 0.31 LPL
rs2281727 17 0.36 C/T 1.05 7.8×10−9 0.25 1.07 (0.99–1.15) 0.09 0.34 1.02 (0.96–1.09) 0.50 SMG6
rs445925 19 0.9 C/T 1.13 8.8×10−9 0.54 1.16 (0.97–1.39) 0.10 0.56 1.05 (0.92–1.19) 0.46 APOC1
rs10947789 6 0.76 T/C 1.06 9.8×10−9 0.36 1.12 (1.02–1.22) 0.01 0.48 1.13 (1.05–1.22) 5.6×10−4 KCNK5
rs579459 9 0.21 C/T 1.07 2.7×10−8 0.33 1.06 (0.97–1.17) 0.20 0.45 1.03 (0.96–1.12) 0.39 ABO
rs2252641 2 0.46 G/A 1.04 5.3×10−8 0.36 1.00 (0.92–1.07) 0.91 0.48 0.97 (0.91–1.03) 0.34 ZEB2
rs12413409 10 0.89 G/A 1.10 6.3×10−8 0.38 1.05 (0.92–1.20) 0.49 0.52 1.01 (0.90–1.13) 0.91 CNNM2
rs9326246 11 0.10 C/G 1.09 1.5×10−7 0.51 0.93 (0.79–1.08) 0.32 0.41 0.93 (0.82–1.06) 0.26 BUD13
rs11203042 10 0.44 T/C 1.04 6.1×10−6 0.19 1.05 (0.98–1.13) 0.15 0.25 1.07 (1.01–1.14) 0.03 LIPA
rs15563 17 0.52 C/T 1.04 9.4×10−6 0.19 1.12 (1.04–1.20) 1.9×10−3 0.25 1.07 (1.01–1.13) 0.03 UBE2Z
rs2246833 10 0.38 T/C 1.06 9.5×10−6 0.34 1.07 (1.00–1.16) 0.06 0.46 1.06 (1.00–1.13) 0.05 LIPA
rs11206510 1 0.84 T/C 1.06 1.8×10−5 0.22 1.02 (0.92–1.14) 0.67 0.30 1.01 (0.93–1.10) 0.80 PCSK9
rs12205331 6 0.81 C/T 1.04 4.2×10−5 0.14 1.03 (0.93–1.13) 0.58 0.17 1.05 (0.97–1.13) 0.24 ANKS1A
rs17464857 1 0.87 T/G 1.05 6.1×10−5 0.15 1.11 (0.97–1.27) 0.13 0.19 1.09 (0.97–1.22) 0.14 TAF1A
(Continued)
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In this two-stage design, we found evidence for MI-associated genetic variants nearby QKI
(KH domain containing, RNA binding). The combined p-value for three out of four genetic
variants that were examined in the region exceeded genome-wide significant threshold.
Although these data provide evidence for an association between the QKI locus and incident
MI, this finding should be confirmed by further studies since these variants attained conven-
tional levels of genome-wide significant p-value only in the combined meta-analysis.
If confirmed, the QKI finding may represent a novel pathway in developing CHD. QKI is
known to be involved in cell cycle regulation, a pathway for which there is emerging evidence for
a key role in developing atherosclerotic plaques and cardiovascular disease [18, 19]. A functional
study has reported thatQKI is a central regulator of vascular smooth muscle cell phenotypic plas-
ticity and that intervention inQKI activity can improve pathogenic fibro-proliferative responses
to vascular injury [20]. Moreover, a recent paper shows that the RNA-binding properties of QKI
play a critical role in regulating humanmonocyte to macrophage differentiation [21]. de Bruin
and co-workers identified that the conversion of monocytes to both pro- and anti-inflammatory
macrophages with GM-CSF or M-CSF, respectively, markedly increased expression of the QKI,
which all were readily detected in CD68+ macrophages of fibrous cap atheromata and atheroscle-
rotic lesions with intraplaque hemorrahage. Furthermore, reduced expression of QKI in mono-
cytes delayed their differentiation into macrophages, perturbed their capacity to become lipid-
engorged foam cells, and led to a reduction in monocyte infiltration in atherosclerotic lesions
[21]. Altogether we propose that QKI is involved in inflammatory responses to injury and could
be a potential thrapeutic target to prevent cardiovascular disease. Further functional investigation
is needed to robustly identify mechanisms involved for this locus.
Prior GWAS which included extremely large sample sizes did not report QKI though they
should have had enough statistical power to detect a locus with such an effect. However
rs6941513 was not associated with CAD in the Cardiogram plusC4D GWAS (OR = 1.01, p-
value = 0.45). In contrast to former GWAS, we have used a prospective, longitudinal cohort
design to examine genetic association with incident cases of MI and CHD. It is possible that
the magnitude of the effect with prevalent cases is smaller than with incident cases; thus the
locus was not detected by previously published GWAS that primarily use a case-control design.
Although CHD includes MI events by definition, the loci we found for MI and CHD over-
lapped only for one locus (ATX1). One reason could be differences in mechanisms involved in
the restrictive diagnosis of MI versus the broader diagnosis of CHD. However, unstable effect
Table 4. (Continued)
SNP Chr. Freq. Alleles* Reported
GWAS
GWAS on Incident MI GWAS on Incident CHD Gene
OR P-value Power HR (95% CI) P-value Power HR (95% CI) P-value
rs12539895 7 0.19 A/C 1.08 5.3×10−4 0.39 1.03 (0.94–1.12) 0.57 0.52 0.99 (0.92–1.07) 0.87 GPR22
Chr. = Chromosome; Freq. = Frequency; OR = Odds Ratio; HR = Hazard Ratio; CI = Conﬁdence Interval
*Coded / Non-coded allele
doi:10.1371/journal.pone.0144997.t004
Table 5. Association of the known SNPs for coronary artery disease with mortality after MI.
SNP Closest Gene Alleles HR(95%CI) P-value
rs1333049 CDKN2A/B C/G 0.90 (0.84–0.97) 5.5×10−3
rs3217992 CDKN2A/B A/G 0.94 (0.88–1.01) 0.10
rs602633 PSRC1 C/A 1.01 (0.93–1.09) 0.93
doi:10.1371/journal.pone.0144997.t005
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estimates and p-values due to lack of statistical power could have contributed to this observa-
tion as well.
Despite excellent statistical power, we identified only a modest signal at the 9p21 locus. This
locus, initially identified by GWAS, has been validated by numerous studies in different geo-
graphic and ethnic subgroups. However, our study is not the first study to report a weak signal
or lack of association at this locus. In fact, prominent differences have been observed between
cross-sectional case-control versus longitudinal studies. For instance, in a meta-analysis by
Chan et al [22], cross-sectional analyses of angiographically defined cases and controls show a
strong per allele association with 9p21 (OR: 1.31, 95% CI: 1.20, 1.43). However, in a meta-anal-
ysis of follow-up studies by Patel et al [23], the per allele hazard ratio of the 9p21 variants for
fatal and non-fatal adjudicated MI was 1.09 (95% CI: 1.03–1.16). The latter is the same as what
we report in this study, though the meta-analysis includes earlier reports from some of our
studies. One explanation for this inconsistency is the incidence-prevalence bias. Most GWAS
for coronary artery disease to date have consisted of cross-sectional case-control studies, a
design that over represents patients who survived their MI or CHD event. Using data from five
population based cohort studies we found that the reported risk alleles for this locus are associ-
ated with longer survival after MI. This finding that was previously reported as well [23–25]
supports the conjecture. Thus, the high prevalence of the risk allele in various types of cross-
Fig 3. The association of top 79 SNPs with coronary artery disease as reported by CardiogramplusC4D for 9p21 locus and their association with
total mortality after MI.
doi:10.1371/journal.pone.0144997.g003
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sectional analyses may not be due entirely to a high risk of experiencing MI or CHD, but also
to an improved chance of survival after MI.
The molecular biology behind the protective effect of the risk alleles at 9p21 is yet unclear,
however, there is a growing body of evidence to show that 9p21 locus is only increasing the risk
of CHD for the first event and not for the subsequent events. For instance, Patel et al found no
association with subsequent CHD events in a recent meta-analysis of 25,163 individuals with
established CHD [23]. Thus, it could be concluded that 9p21 locus is contributing to the forma-
tion and progression of plaques and not to their instability prior to events; therefore, the associa-
tion is merely observed in early stages of the disease. This is in agreement with the report by
Palomaki [26] that suggests a diminished effect of 9p21 locus by age, a finding that is confirmed
by Patel et al for secondary events. It should be noted that the mean age of participants was more
than 70 years old in two and more than 60 years old in four of the participating cohorts. In this
context, the older mean age of our population could be another reason why our findings do not
replicate known loci such as 9p21.Our study is the largest collection of population-based pro-
spective GWAS on incident MI and CHD and includes high quality genotyping and phenotyping
data from well-known cohort studies in the field of cardiovascular disease. Moreover, similar
case definitions for MI and CHD, comparable quality control for genotyped data, harmonized
imputation strategies and collaboratively designed analysis plans are further strengths of our
study. Despite these strengths, there are several limitations that merit discussion. First, nearly all
studies who contributed to our GWAS are also members of the CARDIoGRAMPlusC4D Con-
sortium [27], however, they have used only their prevalent cases in CARDIoGRAMPlusC4D
project and therefore there is no overlap between the two GWAS. Second, since our sample size
was limited, further susceptibility variants of weaker effects may have been missed in our study.
Third, we have tried to use consistent definitions for MI, however, slight differences exist between
the definitions for CHD. This might have introduced heterogeneity in our case definition. Finally,
our findings may not be directly generalizable to non-European populations.
A potential clinical application of risk alleles identified from GWAS is the prospective pre-
diction of cardiovascular disease. To date, the totality of evidence from prospective studies sug-
gests that there is only modest, independent prediction of increased cardiovascular disease risk
using genetic information with small to modest incremental reclassification for prediction
beyond the known clinical CVD risk scores [28]. This lack of success has been attributed to the
small percentage of variance explained by known genetic factors. However, our results also sug-
gest that genetic risk prediction needs to consider differences in genetic variants that predict
the risk of cardiovascular disease in prospective and cross-sectional settings.
In summary, using the largest collection of population- based prospective genome-wide
association studies we have identified QKI as a potential locus for incident myocardial infarc-
tion. Furthermore, we have shown that the genes associated with risk of cardiovascular disease
may differ in effect size when studied in a cross-sectional case-control versus cohort settings.
The role of 9p21 locus may be complex, increasing the risk of incident MI and decreasing mor-
tality among those with CHD. This highlights the importance of examining longitudinal cohort
studies in the study of etiology even for genetic factors. These findings may have implications
for application of genetic variants in risk estimation for cardiovascular disease, an effort that so
far has not provided strong evidence for incremental risk prediction by genetic markers.
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